In conclusion, we identified a new candidate oncogenic lncRNA WFDC21P that promotes tumor progression through WFDC21P/Ran/Akt/GSK3β/β-catenin axis and that is positively regulated by transcription factor FOXP3 in GC, which may provide a novel biomarker and therapeutic target for GC. This evidence concerns the gene WFDC21P and neoplasm.